The reporting of prostate cancer on needle biopsy: prognostic and therapeutic implications and the utility of diagnostic markers

References

• Epstein JI, Yang XM. Prostate biopsy interpretation, 3rd ed. Philadelphia: Lippincott William and Wilkins, 2002.
   Google Scholar
• Bostwick DG, Dundore PA. Biopsy pathology of the prostate, 1st ed. London, New York: Chapman and Hall Medical, 1997.
   Google Scholar
• Epstein JI. The diagnosis and reporting of adenocarcinoma of the prostate in core needle biopsy specimen. Cancer 1996; 78: 350–6.
   PubMed Web of Science ®Google Scholar
• Thorson P, Humphrey PA. Minimal adenocarcinoma in prostate needle biopsy tissue. Am J Clin Pathol 2000; 114: 896–909.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Iczkowski KA. Minimal criteria for the diagnosis of prostate cancer on needle biopsy. Ann Diagn Pathol 1997; 1: 104–29.
   PubMedGoogle Scholar
• Gleason DF, Mellinger GT and the Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoma by combined histologic grading and clinical staging. J Urol 1974; 111: 58–64.
   Google Scholar
• Epstein JI, Partin AW, Sauvageot J, et al. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996; 20: 286–92.
   PubMed Web of Science ®Google Scholar
• McNeal JE, Villers AA, Redwine EA, et al. Histologic differentiation, cancer volume, and pelvic lymph node metastasis in adenocarcinoma of the prostate. Cancer 1990; 66: 1225–33.
   PubMed Web of Science ®Google Scholar
• Epstein JI. Gleason score 2-4 adenocarcinoma of the prostate on needle biopsy: a diagnosis that should not be made. Am J Surg Pathol 2000; 24: 477–8.
   PubMed Web of Science ®Google Scholar
• Steinberg DM, Sauvageot J, Piantadosi S, et al. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 1997; 21: 566–76.
   PubMed Web of Science ®Google Scholar
• Allsbrook W Jr., Lane R, Lane C, et al. Interobserver reproducibility of Gleason's grading system. Urologic Pathologists. Hum Pathol 2001; 32: 74–80.
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Hanley JA, Gleason DF, et al. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975–80.
   PubMed Web of Science ®Google Scholar
• McNeal JE, Redwine EA, Freiha FS, et al. Zonal distribution of prostatic adenocarcinoma: Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988; 12: 897–906.
   PubMed Web of Science ®Google Scholar
• McNeal JE. Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum Pathol 1992; 23: 258–66.
   PubMed Web of Science ®Google Scholar
• Greene DR, Wheeler TM, Egawa S, et al. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Brit J Urol 1991; 68: 499–509.
   PubMedGoogle Scholar
• Bostwick DG. Gleason grading of prostatic needle biopsies. Correla-tion with grade in 316 matched prostatectomies. Am J Surg Pathol 1994; 18: 796–803.
   PubMed Web of Science ®Google Scholar
• Spires SE, Cibull ML, Wood DP Jr, et al. Gleason histologic grading in prostatic carcinoma. Correlation of I8-guage-core biopsy with prostatectomy. Arch Pathol Lab Med 1994; 118: 705–8.
   PubMed Web of Science ®Google Scholar
• San Francisco IF, DeWolf WC, Rosen S, et al. Extended prostate needle biopsy improves concordance of Gleason grading between prostate needle biopsy and radical prostatectomy. J Urol 2003; 169: 136–40.
   PubMed Web of Science ®Google Scholar
• Narayan P, Gajendran V, Taylor SP, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995; 46: 205–12.
   PubMed Web of Science ®Google Scholar
• Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict patho-logical stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445–51.
   Google Scholar
• Kattan MW, Eastham JA, Stapleton AMF, et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998; 90: 766–71.
   PubMed Web of Science ®Google Scholar
• D'Amico AY, Whittington R, Malcowicz SB, et al. Combination of preoperative PSA level, biopsy Gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology 200; 55: 572–7.
   Google Scholar
• Badalament RA, Miller MC, Peller PA, et al. An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. J Urol 1996; 156: 1375–80.
   PubMed Web of Science ®Google Scholar
• Huland H, Hammerer P, Henke RP, et al. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies. J Urol 1996; 155: 1344–7.
   PubMed Web of Science ®Google Scholar
• Peller PA, Young DC, Marmaduke DP, et al. Sextant prostate biopsies: a histopathologic correlation with radical prostatectomy specimens. Cancer 1995; 75: 530–8.
   PubMed Web of Science ®Google Scholar
• Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, et al. Systemic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994; 44: 371–6.
   PubMed Web of Science ®Google Scholar
• Wills ML, Sauvageot J, Partin AW, et al. Ability of sextant biopsies to predict radical prostatectomy stage. Urology 1998; 51: 759–64.
   PubMed Web of Science ®Google Scholar
• Sebo Ti, Bock BJ, Cheville JC, et al. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol 2000; 163: 174–8.
   PubMed Web of Science ®Google Scholar
• Terris MK, Haney DJ, Johnstone IM, et al. Prediction of prostate cancer volume using prostate-specific antigen levels, transrectal ultrasound, and systemic sextant biopsies. Urology 1995; 45: 75–80.
   PubMed Web of Science ®Google Scholar
• Conrad S, Graefen M, Pichlmeier U, et al. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma. J Urol 1998; 159: 2023–9.
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Baty J, Keetch D. Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. Cancer 1995; 75: 1842–9.
   Google Scholar
• Ackerman DA, Barry JM, Wicklund RA, et al. Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. J Urol 1993; 159: 1845–50.
   Web of Science ®Google Scholar
• Tigrani VS, Bhargava V, Shinohara K, et al. Number of positive systematic sextant biopsies predicts surgical margin status at radical prostatectomy. Urology 1999; 54: 689–93.
   PubMed Web of Science ®Google Scholar
• Presti JC Jr., Shinohara K, Bacchetti P, et al. Positive fraction of systematic biopsies predicts risk of relapse after radical prostatectomy. Urology 1998; 52: 1079–84.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Qian J, Bergstralh E, et al. Prediction of capsular perforation and seminal vesicle invasion in prostate cancer. J Urol 1996; 155: 1361–7.
   PubMed Web of Science ®Google Scholar
• Cupp MR, Bostwick DG, Myers RP, et al. The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J Urol 1995; 53: 1543–8.
   Web of Science ®Google Scholar
• Ravery V, Schmid HP, Toublanc M, et al. Is the percentage of cancer in biopsy cores predictive of extracapsular disease in T1-T2 prostate carcinoma? Cancer 1996; 78: 1079–84.
   PubMed Web of Science ®Google Scholar
• Ukimura O, Troncoso P, Ramirez El, et al. Prostate cancer staging: correlation between determined tumor contact length and pathologi-cally confirmed extraprostatic extension. J Urol 1998; 159: 1251–9.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Bassily N, Sanda M, et al. Relationship and significance of greatest percentage of tumor and perineural invasion on needle biopsy in prostatic adenocarcinoma. Am J Surg Pathol 2000; 24: 183–9.
   PubMed Web of Science ®Google Scholar
• Bruce RG, Rankin WR, Cibull ML, et al. Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. Urology 1996; 48: 75–79.
   PubMed Web of Science ®Google Scholar
• Dietrick DD, McNeal JE, Stamey TA. Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evalua-tion of prostate cancer volume. Urology 1995; 45: 987–92.
   Google Scholar
• Epstein JI, Walsh PC, CarMichael M, et al. Pathological and clinical findings to predict tumor extent of non-palpable (stage Tic) prostate cancer. JAMA 1994; 271: 368–74.
   PubMed Web of Science ®Google Scholar
• Wang X, Brannigan RE, Rademaker AW, et al. One core positive prostate biopsy is a poor predictor of cancer volume in the radical prostatectomy specimen. J Urol 1997; 158: 1431–5.
   PubMed Web of Science ®Google Scholar
• Weldon V, Tavel FR, Neuwirth H, et al. Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J Urol 1995; 154: 1074–7.
   PubMed Web of Science ®Google Scholar
• Freedland Si, Aronson WJ, Csathy GS, et al. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database. Urology 2003; 61: 742–7.
   PubMed Web of Science ®Google Scholar
• Bismar TA, Lewis JS, Voller RT, et al. Multiple measures of carcinoma extent versus perineural invasion in prostate needle biopsy tissue in prediction of pathologic stage in a screening population. Am J Surg Pathol 2003; 27: 432–40.
   PubMed Web of Science ®Google Scholar
• Taneja SS, Penson DF, Epelbaum A, et al. Does site specific labeling of sextant biopsy cores predict the site of extraprostatic extension in radical prostatectomy surgical specimen? J Urol 1999; 162: 1352–8.
   PubMed Web of Science ®Google Scholar
• Allen EA, Kahane H, Epstein JI. Repeat biopsy strategies for men with atypical diagnoses on initial prostate needle biopsy. Urology 1998; 52: 803–7.
   Google Scholar
• Calvanese CB, Kahane H, Carlson GD, et al. Presurgical staging of prostate cancer. Infections in Urology 1999; 12: 22–8.
   Web of Science ®Google Scholar
• Epstein JI, Lecksell K, Carter HB. Prostate cancer sampled on sextant needle biopsy: significance of cancer on multiple cores from different areas of the prostate. Urology 1999; 54: 291–4.
   Google Scholar
• Byar DP, Mostofi FK and the Veterans Administration Cooperative Urological Research Group. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatec-tomies. Cancer 1972; 30: 5–13.
   Google Scholar
• Villers A, McNeal JE, Redwine EA, et al. The role of perineural invasion in the local spread of prostatic adenocarcinoma. J Urol 1989; 142: 763–768.
   PubMed Web of Science ®Google Scholar
• Bastacky SI, Walsh PC, Epstein JI. Relationship between perineural tumor invasion on needle biopsy and radical prostatectomy capsular penetration in clinical stage B adenocarcinoma of the prostate. Am J Surg Pathol 2003; 17: 336–41.
   Google Scholar
• Holmes GF, Walsh PC, Pound CR, et al. Excision of the neurovascular bundle at radical prostatectomy in cases with perineural invasion on needle biopsy. Urology 1999; 53: 752–6.
   PubMed Web of Science ®Google Scholar
• De la Taille A, Katz A, Bagiella E, et al. Perineural invasion on prostate needle biopsy: an independent predictor of final pathologic stage. Urology 1999; 54: 1039–43.
   PubMed Web of Science ®Google Scholar
• Egan AJM, Bostwick DG. Prediction of extraprostatic extension of prostate cancer based on needle biopsy findings: Perineural invasion lacks significance on multivariate analysis. Am J Surg Pathol 1997; 21: 1496–1500.
   PubMed Web of Science ®Google Scholar
• Vargas SO, Jiroutek M, Welch WR, et al. Perineural invasion in prostate needle biopsy specimens. Correlation with extraprostatic extension at resection. Am J Clin Pathol 1999; 111: 223–8.
   PubMed Web of Science ®Google Scholar
• Stone NN, Stock RG, Parikh D, et al. Perineural invasion and seminal vesicle involvement predict lymph node metastasis in men with localized carcinoma of the prostate. J Urol 1998; 160: 1722–6.
   PubMed Web of Science ®Google Scholar
• De la Taille A, Rubin MA, Bagiella E, et al. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy? J Urol 1999; 162: 103–6.
   PubMed Web of Science ®Google Scholar
• Bostwick DG, Wheeler TM, Blute M, et al. Optimized microvessel density analysis improves prediction of cancer stage from prostate needle biopsies. Urology 1996; 48: 47–57.
   PubMed Web of Science ®Google Scholar
• Brinker DA, Ross JS, Tran TA, et al. Can ploidy of prostate carcinoma diagnosed on needle biopsy predict radical prostatectomy stage and grade? J Urol 1999; 162: 2036–9.
   PubMed Web of Science ®Google Scholar
• Ross JS, Figge H, Bui HX, et al. Prediction of pathologic stage and postprostatectomy disease recurrence by DNA ploidy analysis of initial needle biopsy specimens of prostate cancer. Cancer 1994; 74: 2811–8.
   PubMed Web of Science ®Google Scholar
• Ross JS, Sheehan CE, Ambros RA, et al. Needle biopsy DNA ploidy status predicts grade shifting in prostate cancer. Am J Surg Pathol 1999; 23: 296–301.
   PubMed Web of Science ®Google Scholar
• Zhang YH, Kanamaru H, Oyama N, et al. Prognostic value of nuclear morphometry on needle biopsy from patients with prostate cancer: is volume-weighted mean nuclear volume superior to other morphometric parameters? Urology 2000; 55: 377–81.
   PubMed Web of Science ®Google Scholar
• Freedland Si, DeGregorio F, Sacoolidge JC, et al. Preoperative p27 status is an independent predictor of prostate specific antigen failure following radical prostatectomy. J Urol 2003; 169: 1325–30.
   PubMed Web of Science ®Google Scholar
• Vis AN, van Rhijn BWG, Noordzij MA, et al. Value of tissue markers p27kiP1, MIB-1, and CD44s for the pre-operative prediction of tumour features in screen-detected prostate cancer. J Pathol 2002; 197: 148–54.
   PubMed Web of Science ®Google Scholar
• Diaz .11, Mora LB, Austin PF, et al. Predictability of PSA failure in prostate cancer by computerized cytometric assessment of tumor cell proliferation. Urology 1999; 53: 931–8.
   Google Scholar
• Brewster SF, Oxley JD, Trivella M, et al. Preoperative p53, bc1-2, CD44 and e-cadherin immunohistochemistry as predictors of biochemical relapse after radical prostatectomy. J Urol 1999; 161: 1238–43.
   PubMed Web of Science ®Google Scholar
• Pollack A, Cowen D, Troncoso P, et al. Molecular markers of outcome after radiotherapy in patients with prostate carcinoma. Cancer 2003; 97: 1630–8.
   PubMed Web of Science ®Google Scholar
• Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994; 91: 11733–7.
   PubMed Web of Science ®Google Scholar
• Lee WH, Isaacs WB, Bova GS, et al. CG island methylation changes near the GSTP1 gene in prostatic carcinoma cells detected using the polymerase chain reaction: a new prostate cancer biomarker. Cancer Epidemiol Biomarkers Prey 1997; 6: 443–50.
   PubMed Web of Science ®Google Scholar
• Jeronimo C, Usadel H, Henrique R, et al. Quantitation of GSTP1 methylation in non-neoplastic prostatic tissue and organ-confined prostate adenocarcinoma. J Natl Cancer Inst 2001; 93: 1747–52.
   PubMed Web of Science ®Google Scholar
• Harden SV, Guo C, Epstein JI, et al. Quantitative GSTP1 methylation clearly distinguishes benign prostatic tissue and limited prostate adenocarcinoma. J Urol 2003; 169: 1138–42.
   PubMed Web of Science ®Google Scholar
• Hedrick L, Epstein JI. Use of keratin 903 as an adjunct in the diagnosis of prostate carcinoma. Am J Surg Pathol 1989; 13: 389–96.
   PubMed Web of Science ®Google Scholar
• Ramnani DM, Bostwick DG. Basal cell-specific anti-keratin antibody 34betaE12: optimizing its use in distinguishing benign prostate and cancer. Mod Pathol 1999; 12: 443–4.
   PubMed Web of Science ®Google Scholar
• Abrahams NA, Ormsby AH, Brainard J. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histo-pathology 2002; 41: 35–41.
   Google Scholar
• Bostwick DG, Srigley J, Grignon D, et al. Atypical adenomatous hyperplasia of the prostate: morphologic criteria for its distinction from well-differentiation carcinoma. Hum Pathol 1993; 24: 819–832.
   PubMed Web of Science ®Google Scholar
• Gaudin PB, Epstein JI. Adenosis of the prostate. Histologic features in needle biopsy specimens. Am J Surg Pathol 1995; 19: 737–47.
   PubMed Web of Science ®Google Scholar
• Goldstein NS, Underhill J, Roszka J, et al. Cytokeratin 34 beta E-12 immunoreactivity in benign prostatic acini. Quantitation, pattern assessment, and electron microscopic study. Am J Surg Pathol 1999; 112: 69–74.
   Google Scholar
• Signoretti S, Walregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769–75.
   PubMed Web of Science ®Google Scholar
• Shah RB, Zhou M, LeBlanc M, et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol 2002; 26: 1161–8.
   PubMed Web of Science ®Google Scholar
• Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostate basal cells. Mod Pathol 2002; 15: 1302–8.
   Google Scholar
• Zhou M, Shah R, Shen R, et al. Basal cell cocktail (34betaE12+p63) improves the detection of prostate basal cells. Am J Surg Pathol 2003; 27: 365–71.
   PubMed Web of Science ®Google Scholar
• Ferdinandusse S, Denis S, Ulst L, et al. Subcellular localization and physiological role of alpha-methylacyl-CoA racemase. J Lipid Res 2000; 41: 1890–6.
   PubMed Web of Science ®Google Scholar
• Zhou M, Chinnayian AM, Kleer CG, et al. Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol 2002; 26: 926–31.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Woda BA, Rock KL, et al. P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 2001; 25: 1397–1404.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Zhou M, Dhanasekaran SM, et al. alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA 2002; 287: 1662–70.
   PubMed Web of Science ®Google Scholar
• Luo J, Zha S, Gage WR, et al. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 2002; 62: 2220–6.
   PubMed Web of Science ®Google Scholar
• Jiang Z, Wu C-L, Woda BA, et al. P5045/alpha-methylacyl-CoA racemase. A useful marker for diagnosis of small foci of prostatic carcinoma on needle biopsy. Am J Surg Pathol 2002; 26: 1169–74.
   Google Scholar
• Beach R, Gown AM, de Peralta-Venturina MN, et al. P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies. Am J Surg Pathol 2002; 26: 1588–96.
   Google Scholar
• Zhou M, Jiang Z, Epstein JI. Expression and diagnostic utility of alpha-methyacyl-coA-racemase (P504S) in foamy gland and pseudo-hyperplastic prostate cancer. Am J Surg Pathol 2003; 27: 772–8.
   Google Scholar
• Yang Xi, Wu CL, Woda BA, et al. Expression of alpha-Methylacyl-CoA racemase (P504S) in atypical adenomatous hyperplasia of the prostate. Am J Surg Pathol 2002; 26: 921–5.
   PubMed Web of Science ®Google Scholar
• Zhou M, Aydin H, Kahane H, et al. How often does alpha-methylacyl-CoA-racemase contribute to resolving an atypical diag-nosis on prostate needle biopsy beyond that provided by basal cell markers? Am J Surg Pathol 2003 [in press].
   Google Scholar
• Liu W, Jiang Z, Tretiakova M, et al. Application of alpha-methylacyl-CoA racemase immunostaining in previously negative prostate biopsies. Mod Pathol 2003; 16: 159.
   Web of Science ®Google Scholar